Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

NCT03708536 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER_GOV

Sponsor class

Stopped There are no fund to support

Conditions

Colorectal Adenocarcinoma

Interventions

DRUG: S-1
DRUG: Bevacizumab
DRUG: Capecitabine

Sponsor

Fujian Cancer Hospital